A phase 1 study of everolimus plus docetaxel plus cisplatin as induction chemotherapy for patients with locally and/or regionally advanced head and neck cancer-Reference-Cited by-同舟云学术

A phase 1 study of everolimus plus docetaxel plus cisplatin as induction chemotherapy for patients with locally and/or regionally advanced head and neck cancer

Published:2013-02-13 Issue:10 Volume:119 Page:1823-1831
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Fury Matthew G.,Sherman Eric,Ho Alan L.,Xiao Han,Tsai Frank,Nwankwo Oby,Sima Camelia,Heguy Adrian,Katabi Nora,Haque Sofia,Pfister David G.

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference39 articles.

1. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer;Posner;N Engl J Med.,2007

2. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer;Vermorken;N Engl J Med.,2007

3. Induction therapy in the modern era of combined-modality therapy for locally advanced head and neck cancer;Posner;Semin Oncol.,2008

4. Induction chemotherapy in the management of head and neck cancer;Fury;J Surg Oncol.,2010

5. NCCN task force report: mTOR inhibition in solid tumors;Figlin;J Natl Compr Canc Netw.,2008

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pembrolizumab Plus Carboplatin and Paclitaxel as First-Line Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-B10): A Single-Arm Phase IV Trial;Journal of Clinical Oncology;2024-09-01

2. The Role of the PI3K/Akt/mTOR Axis in Head and Neck Squamous Cell Carcinoma;Biomedicines;2024-07-19

3. The Role of mTORC1 Pathway and Autophagy in Resistance to Platinum-Based Chemotherapeutics;International Journal of Molecular Sciences;2023-06-26

4. EGFR pathway targeting drugs in head and neck cancer in the era of immunotherapy;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2023-01

5. First-line everolimus and cisplatin in patients with advanced extrapulmonary neuroendocrine carcinoma: a nationwide phase 2 single-arm clinical trial;Therapeutic Advances in Medical Oncology;2022-01